Q4 2014 13F Holders as of 12/31/2014
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
120M
-
Shares change
-
+1.15M
-
Total reported value, excl. options
-
$1.86B
-
Value change
-
+$32.2M
-
Put/Call ratio
-
0.54
-
Number of buys
-
80
-
Number of sells
-
-68
-
Price
-
$15.50
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2014
191 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2014.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 120M shares
.
Largest 10 shareholders include OPPENHEIMER FUNDS INC (24.2M shares), PRIMECAP MANAGEMENT CO/CA/ (18.2M shares), VANGUARD GROUP INC (8.3M shares), FIRST TRUST ADVISORS LP (5.01M shares), FEDERATED INVESTORS INC /PA/ (4.99M shares), JPMORGAN CHASE & CO (4.86M shares), BlackRock Fund Advisors (4.73M shares), Invesco Ltd. (4.13M shares), State Street Corp (4.12M shares), and GRANAHAN INVESTMENT MANAGEMENT INC/MA (3.51M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.